MIRA INFORM REPORT

 

 

Report Date :

26.11.2013

 

IDENTIFICATION DETAILS

 

Name :

PHARMACODANE APS

 

 

Registered Office :

Marielundvej 46 A, Herlev, 2730

 

 

Country :

Denmark

 

 

Financials (as on) :

31.12.2012

 

 

Date of Incorporation :

1990

 

 

Com. Reg. No.:

13902992

 

 

Legal Form :

Private Subsidiary

 

 

Line of Business :

Subject is engaged in the merchant wholesale distribution of biological and medical products; botanical drugs and herbs; and pharmaceutical products intended for internal and external consumption in such forms as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

 

 

No. of Employees :

35

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

Slow but correct

Litigation :

Clear

 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March, 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Denmark

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 


 

DENMARK - ECONOMIC OVERVIEW

 

This thoroughly modern market economy features a high-tech agricultural sector, state-of-the-art industry with world-leading firms in pharmaceuticals, maritime shipping and renewable energy, and a high dependence on foreign trade. Denmark is a member of the European Union (EU); Danish legislation and regulations conform to EU standards on almost all issues. Danes enjoy a high standard of living and the Danish economy is characterized by extensive government welfare measures and an equitable distribution of income. Denmark is a net exporter of food and energy and enjoys a comfortable balance of payments surplus but depends on imports of raw materials for the manufacturing sector. Within the EU, Denmark is among the strongest supporters of trade liberalization. After a long consumption-driven upswing, Denmark's economy began slowing in 2007 with the end of a housing boom. Housing prices dropped markedly in 2008-09 and, following a short respite in 2010, has since continued to decline. The global financial crisis has exacerbated this cyclical slowdown through increased borrowing costs and lower export demand, consumer confidence, and investment. The global financial crisis cut Danish real GDP in 2008-09. Denmark made a modest recovery in 2010 with real GDP growth of 1.3%, in part because of increased government spending; however, the country experienced a technical recession in late 2010-early 2011. Historically low levels of unemployment rose sharply with the recession and have remained at about 6% in 2010-12, based on the national measure, about two-thirds average EU unemployment. An impending decline in the ratio of workers to retirees will be a major long-term issue. Denmark maintained a healthy budget surplus for many years up to 2008, but the budget balance swung into deficit in 2009. In spite of the deficits, the new coalition government delivered a modest stimulus to the economy in 2012. Nonetheless, Denmark's fiscal position remains among the strongest in the EU with public debt at about 45% of GDP in 2012. Despite previously meeting the criteria to join the European Economic and Monetary Union (EMU), so far Denmark has decided not to join, although the Danish krone remains pegged to the euro.

 

Source : CIA

 


Company name & address


 

 

PHARMACODANE APS 

                                                                                                                                                                                                                                                                                                                                                                           

 

Marielundvej 46 A

 

 

Herlev, 2730

Denmark

 

 

Tel:

45-44859999

Fax:

45-44-85-15-99

 

 www.pharmacodane.dk

 

Employees:

35

Company Type:

Private Subsidiary

Corporate Family:

69 Companies

Ultimate Parent:

STADA Arzneimittel AG

 

 

Incorporation Date:

1990

Financials in:

               

 

 

Fiscal Year End:

31-Dec-2012

Reporting Currency:

Danish Krone

Annual Sales:

35.0

Net Income:

0.3

Total Assets:

28.4

                                     

 

Business Description

 

 

Pharmacodane ApS is primarily engaged in the merchant wholesale distribution of biological and medical products; botanical drugs and herbs; and pharmaceutical products intended for internal and external consumption in such forms as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

 

 

Industry

 

 

Industry

Pharmaceutical Manufacturing

ANZSIC 2006:

1841 - Human Pharmaceutical and Medicinal Product Manufacturing

ISIC Rev 4:

2100 - Manufacture of pharmaceuticals, medicinal chemical and botanical products

NACE Rev 2:

2120 - Manufacture of pharmaceutical preparations

NAICS 2012:

325412 - Pharmaceutical Preparation Manufacturing

UK SIC 2007:

2120 - Manufacture of pharmaceutical preparations

US SIC 1987:

2834 - Pharmaceutical Preparations

 

 

Key Executives   

 

Name

Title

Inge Merete Larsen

General Manager

Luc Maurice Godelieva Slegers

Bestyrelsesformand

 

      

 

 


News 

 

Title

Date

Denmark-Copenhagen: Pharmaceutical products
Tenders Electronic Daily (2160 Words)

13-Nov-2013

Denmark-København Ă˜: Pharmaceutical products
Tenders Electronic Daily (3214 Words)

31-Oct-2013

Denmark-Copenhagen: Pharmaceutical products
Tenders Electronic Daily (1057 Words)

27-Aug-2013

 

 

Registered No.(DNK): 13902992

 

1 - Profit & Loss Item Exchange Rate: USD 1 = DKK 5.793028 


2 - Balance Sheet Item Exchange Rate: USD 1 = DKK 5.6443

 

 

Corporate Overview

 

Location
Marielundvej 46 A
Herlev, 2730
Denmark

 

Tel:

45-44859999

Fax:

45-44-85-15-99

 

www.pharmacodane.dk

Sales DKK(mil):

202.8

Assets DKK(mil):

160.5

Employees:

35

Fiscal Year End:

31-Dec-2012

 

 

 

Industry:

Biotechnology and Drugs

Incorporation Date:

1990

Company Type:

Private Subsidiary

Quoted Status:

Not Quoted

Registered No.(DNK):

13902992

 

Bestyrelsesformand:

Luc Maurice Godelieva Slegers

 

 

Industry Codes

 

ANZSIC 2006 Codes:

1841

-

Human Pharmaceutical and Medicinal Product Manufacturing

 

ISIC Rev 4 Codes:

2100

-

Manufacture of pharmaceuticals, medicinal chemical and botanical products

 

NACE Rev 2 Codes:

2120

-

Manufacture of pharmaceutical preparations

 

NAICS 2012 Codes:

325412

-

Pharmaceutical Preparation Manufacturing

 

US SIC 1987:

2834

-

Pharmaceutical Preparations

 

UK SIC 2007:

2120

-

Manufacture of pharmaceutical preparations

 

 

Business Description

 

Pharmaceutical Products Mfr

 

 

More Business Descriptions

 

Pharmacodane ApS is primarily engaged in the merchant wholesale distribution of biological and medical products; botanical drugs and herbs; and pharmaceutical products intended for internal and external consumption in such forms as ampoules, tablets, capsules, vials, ointments, powders, solutions, and suspensions.

 

 

Financial Data

 

Financials in:

DKK(mil)

 

Revenue:

202.8

Net Income:

1.6

Assets:

160.5

Total Liabilities:

0.0

 

 

 

Date of Financial Data:

31-Dec-2012

 

1 Year Growth

NA

NA

NA

 

 

Corporate Family

 

Total Corporate Family Members: 69 

 

 

 

Company Name

Company Type

Location

Country

Industry

Sales
(USD mil)

Employees

STADA Arzneimittel AG

Parent

Bad Vilbel

Germany

Pharmaceutical Manufacturing

2,361.2

8,865

Hemofarm AD

Subsidiary

Vršac

Serbia

Pharmaceutical Manufacturing

 

2,482

Hemofarm d.o.o. Å abac

Subsidiary

Å abac

Serbia

Pharmaceutical Manufacturing

 

350

Hemomont d.o.o.

Subsidiary

Podgorica

MonteNegro

Pharmaceutical Manufacturing

 

140

Hemofarm Inzenjering

Subsidiary

Belgrade

Serbia

Nursing and Residential Care

 

67

Hemofarm S.R.L.

Subsidiary

Timisoara

Romania

Pharmaceutical Manufacturing

 

24

Hemofarm Komerc D.O.O.

Subsidiary

Skopje

Macedonia

Pharmaceutical Manufacturing

 

19

Panfarma

Subsidiary

Belgrade

Serbia

Pharmaceutical Manufacturing

 

15

Hemopharm Engineering GmbH

Subsidiary

Bad Homburg

Germany

Pharmaceutical Manufacturing

 

4

Hemovet

Subsidiary

Novi Sad

Serbia

Pharmaceutical Manufacturing

 

 

Hemomont

Subsidiary

Podgorica

Serbia

Pharmaceutical Manufacturing

 

 

Hemofarm A.D.

Subsidiary

Vrsac

Serbia

Pharmaceutical Manufacturing

 

2,000

MOJA APOTEKA d.o.o.

Subsidiary

Vrsac

Serbia

Pharmaceutical Manufacturing

 

1,000

Hemofarm Sabac d.o.o

Subsidiary

Sabac

Serbia

Pharmaceutical Manufacturing

 

357

Zorka Pharma - Hemija Sabac d.o.o

Subsidiary

Sabac

Serbia

Pharmaceutical Manufacturing

 

300

OOO Hemofarm

Subsidiary

Obninsk

Russian Federation

Pharmaceutical Manufacturing

 

150

Hemopharm GmbH

Subsidiary

Bad Homburg

Germany

Pharmaceutical Manufacturing

 

 

Hemofarm Banja Luka d.o.o.

Subsidiary

Banja Luka

Bosnia and Herzegovina

Pharmaceutical Manufacturing

 

 

STADA Hemofarm d.o.o.

Subsidiary

Zagreb

Croatia

Pharmaceutical Manufacturing

 

 

Thornton & Ross Ltd.

Subsidiary

Huddersfield

United Kingdom

Miscellaneous Chemical Manufacturing

95.4

455

Zeroderma Ltd.

Subsidiary

Huddersfield

United Kingdom

Health and Personal Care Wholesale

 

 

Lcm Ltd.

Subsidiary

Huddersfield

United Kingdom

Miscellaneous Professional Services

 

 

ZAO Makiz-Pharma

Subsidiary

Moscow

Russian Federation

Pharmaceutical Manufacturing

 

300

Clonmel Healthcare Limited

Subsidiary

Clonmel

Ireland

Pharmaceutical Manufacturing

 

250

Laboratorio Stada Sl

Subsidiary

Sant Just Desvern, Barcelona

Spain

Pharmaceutical Manufacturing

141.5

185

Genus Pharmaceuticals Ltd.

Subsidiary

Newbury

United Kingdom

Pharmaceutical Manufacturing

103.5

137

Forum Bioscience Holdings Ltd.

Subsidiary

Redhill

United Kingdom

Miscellaneous Professional Services

 

125

Forum Products (Ireland) Ltd.

Subsidiary

Redhill

United Kingdom

Miscellaneous Professional Services

 

 

Quantum Generics Ltd.

Subsidiary

Redhill

United Kingdom

Miscellaneous Professional Services

 

 

EG Labo SAS - Laboratoires Eurogenerics SAS

Subsidiary

Boulogne-Billancourt

France

Pharmaceutical Manufacturing

143.5

92

Eurogenerics

Subsidiary

Bruxelles

Belgium

Health and Personal Care Wholesale

186.8

88

Stada Poland Sp Z O O

Subsidiary

Piaseczno

Poland

Advertising Services

9.2

80

STADApharm GmbH

Subsidiary

Bad Vilbel, Hessen

Germany

Pharmaceutical Manufacturing

 

60

STADA Service Holding B.V.

Subsidiary

Etten-Leur, Noord-Brabant

Netherlands

Pharmaceutical Manufacturing

 

60

Centrafarm Nederland B.V.

Subsidiary

Etten-Leur

Netherlands

Pharmaceutical Manufacturing

73.5

 

Neocare B.V.

Subsidiary

Etten-Leur

Netherlands

Pharmaceutical Manufacturing

 

3

Quatropharma Holding B.V.

Subsidiary

Etten-Leur, Noord-Brabant

Netherlands

Banking

110.1

 

HTP Huisapotheek B.V.

Subsidiary

Etten-Leur, North Brabant

Netherlands

Pharmaceutical Manufacturing

 

 

STADA GmbH

Subsidiary

Bad Vilbel, Hessen

Germany

Pharmaceutical Manufacturing

 

60

Stada Medical Gmbh

Subsidiary

Bad Vilbel, Hessen

Germany

Pharmaceutical Manufacturing

 

 

Centrafarm B.V.

Subsidiary

Etten-Leur

Netherlands

Health and Personal Care Wholesale

 

60

Healthypharm B.V.

Subsidiary

Etten-Leur

Netherlands

Pharmaceutical Manufacturing

 

 

Centrafarm Pharmaceuticals B.V.

Subsidiary

Etten-Leur

Netherlands

Pharmaceutical Manufacturing

 

 

EG S.p.A.

Subsidiary

Milan

Italy

Pharmaceutical Manufacturing

150.0

59

IZGRADNJA d.o.o.

Subsidiary

Crikvenica

Croatia

Architecture and Engineering

 

59

S.A. Eurogenerics N.V.

Subsidiary

Brussels

Belgium

Pharmaceutical Manufacturing

 

50

Hemopharm GmbH Pharmazeutisches Unternehmen

Subsidiary

Bad Homburg, Hessen

Germany

Metal Products Manufacturing

43.2

44

STADA Arzneimittel Gesellschaft m.b.H.

Subsidiary

Vienna

Austria

Pharmaceutical Manufacturing

21.2

40

Ciclum Farma, Unipessoal, LDA

Subsidiary

Paço De Arcos, Oeiras

Portugal

Health and Personal Care Wholesale

19.1

38

PharmaCoDane ApS

Subsidiary

Herlev

Denmark

Pharmaceutical Manufacturing

35.0

35

STADA PHARMA Bulgaria EOOD

Subsidiary

Sofia

Bulgaria

Pharmaceutical Manufacturing

 

30

HEMOPHARM ENGINEERING Gesellschaft fUr Planung und Projektierung mbH

Subsidiary

Bad Homburg, Hessen

Germany

Pharmaceutical Manufacturing

 

30

STADA Pharmaceuticals (Asia) Ltd.

Subsidiary

Kowloon

Hong Kong

Pharmaceutical Manufacturing

 

15

STADA Pharmaceuticals (Beijing) Ltd.

Subsidiary

Beijing

China

Pharmaceutical Manufacturing

 

 

DATApharm Co. Ltd.

Subsidiary

Road Town, Tortola

Virgin Islands (British)

Pharmaceutical Manufacturing

 

 

Crosspharma Ltd.

Subsidiary

Belfast

United Kingdom

Health and Personal Care Wholesale

5.1

13

Crinos S.p.A

Subsidiary

Milan

Italy

Pharmaceutical Manufacturing

58.4

7

Oy Stada Pharma AB

Subsidiary

Helsinki

Finland

Health and Personal Care Wholesale

8.2

6

Oy STADA Pharma Ab

Subsidiary

Helsinki

Finland

Pharmaceutical Manufacturing

 

6

STADApharm AB

Subsidiary

Malmo

Sweden

Pharmaceutical Manufacturing

5.6

 

Croma Medic, Inc.

Subsidiary

Makati

Philippines

Pharmaceutical Manufacturing

 

 

Sadolin Nizhniy Novgorod

Subsidiary

Nizhniy Novgorod

Russian Federation

Miscellaneous Wholesale

 

 

STADA HEMOFARM S.R.L

Subsidiary

Timisoara

Romania

Pharmaceutical Manufacturing

 

 

STADA R&D GmbH

Subsidiary

Bad Vilbel

Germany

Pharmaceutical Manufacturing

 

 

STADA PHARMA CZ, s.r.o.

Subsidiary

Prague

Czech Republic

Pharmaceutical Manufacturing

 

 

OOO STADA CIS

Subsidiary

Nizhniy Novgorod

Russian Federation

Pharmaceutical Manufacturing

 

 

Genus Pharmaceuticals Holdings Ltd.

Subsidiary

Newbury

United Kingdom

Pharmaceutical Manufacturing

 

 

Mobilat Produktions GmbH

Subsidiary

Pfaffenhofen

Germany

Pharmaceutical Manufacturing

 

 

S.A. Neocare N.V.

Subsidiary

Brussels

Belgium

Health and Personal Care Wholesale

 

 

 

 

 

Executives Report

 

Board of Directors

 

 

Name

Title

Function

 

Luc Maurice Godelieva Slegers

 

Bestyrelsesformand

Chairman

 

 

 

Executives

 

 

Name

Title

Function

 

Inge Merete Larsen

 

General Manager

Division Head Executive

 

 

 

News

 

Denmark-Copenhagen: Pharmaceutical products

Tenders Electronic Daily (2160 Words)

13-Nov-2013

Denmark-København Ă˜: Pharmaceutical products

Tenders Electronic Daily (3214 Words)

31-Oct-2013

Denmark-Copenhagen: Pharmaceutical products

Tenders Electronic Daily (1057 Words)

27-Aug-2013



Annual Profit & Loss

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Period Length

12 Months

12 Months

12 Months

Filed Currency

DKK

DKK

DKK

Exchange Rate (Period Average)

5.793028

5.358236

5.623146

Consolidated

No

No

No

 

 

 

 

Total Revenue

35.0

49.2

50.1

Gross Profit

5.0

8.4

7.2

Operating Income

2.5

4.1

3.2

Net Income

0.3

2.9

2.2

 

Annual Balance Sheet

 

Financials in: USD (mil)

 

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Filed Currency

DKK

DKK

DKK

Exchange Rate

5.6443

5.72535

5.55485

Consolidated

No

No

No

 

 

 

 

Total Assets

28.4

24.8

26.1

Provisions

0.6

0.6

0.5

Total Equity

16.7

16.2

13.8

 

 

Annual Ratios

 

 

31-Dec-2012

31-Dec-2011

31-Dec-2010

Period Length

12 Months

12 Months

12 Months

Filed Currency

-

-

-

Exchange Rate

-

-

-

Consolidated

No

No

No

 

 

 

 

Operating Margin

7.09

8.27

6.30

Current Ratio

180.68

227.52

158.82

Total debt/total equity

58.65

65.09

53.00

Return on average equity

1.69

16.93

16.08

 

 

Annual Growth Rates

 

 

 

 

31-Dec-2011

31-Dec-2010

Period Length

12 Months

12 Months

Filed Currency

-

-

Exchange Rate

-

-

Consolidated

No

No

 

 

 

Turnover Percent Change

-23.14%

-6.30%

Marginal Contribution Percent Change

-36.33%

11.70%

Operating Results Percent Change

-34.16%

23.08%

Profit/Loss for the Year Percent Change

-89.82%

26.81%

Assets Percent Change

12.89%

-1.97%

Provisions Percent Change

9.91%

31.99%

Equity Capital Percent Change

1.72%

20.39%

Operating Margin Percent Change

-14.27%

31.27%

Current Ratio Percent Change

-20.59%

43.26%

Debt/Equity Ratio Percent Change

-9.89%

22.81%

Retun On Equity Percent Change

-90.02%

5.29%

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.58

UK Pound

1

Rs.101.42

Euro

1

Rs.84.70

 

 

INFORMATION DETAILS

 

Report Prepared by :

NNA

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.